ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,123.06
0.47%
Dow Jones
43,503.02
0.22%
Gold vs US Dollar
2,664.98
0.47%
Brent Oil
73.565
1.00%
Bitcoin
96,508.69
2.28%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Vivoryon Therapeutics Nv (0R3M)

  7. Vivoryon Therapeutics Nv (0R3M) News

Vivoryon Therapeutics Nv (0R3M)

Vivoryon Therapeutics Nv
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0R3M
DateTimeSourceHeadlineSymbolCompany
26/10/202407:30UK RegulatoryVivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024LSE:0R3MVivoryon Therapeutics Nv
11/10/202413:20UK RegulatoryVivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024LSE:0R3MVivoryon Therapeutics Nv
01/10/202405:00UK RegulatoryVivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL EventLSE:0R3MVivoryon Therapeutics Nv
12/09/202405:00UK RegulatoryVivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney DiseaseLSE:0R3MVivoryon Therapeutics Nv
05/09/202416:12UK RegulatoryVivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of AssociationLSE:0R3MVivoryon Therapeutics Nv
05/09/202405:00UK RegulatoryVivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024LSE:0R3MVivoryon Therapeutics Nv
18/07/202405:00UK RegulatoryVivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney DiseaseLSE:0R3MVivoryon Therapeutics Nv
09/07/202405:00UK RegulatoryVivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney DiseaseLSE:0R3MVivoryon Therapeutics Nv
15/03/202406:00UK RegulatoryVivoryon Therapeutics N.V. Announces Changes to Board CompositionLSE:0R3MVivoryon Therapeutics Nv
04/03/202406:00UK RegulatoryVivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s DiseaseLSE:0R3MVivoryon Therapeutics Nv
 Showing the most relevant articles for your search:LSE:0R3M

Your Recent History

LSE
0JKC
Ishares Silver
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    BLACK FRIDAY

    ADVFN

    Celebrating 25 years Est 1999-2024

    Save up to 60%* for Level 2 Lite

    1 year 40%, 2 years 50% and *3 years 60%
    EU Flag

    *Across 3 years £2132.64 only £853.06